Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 7, 2007 - Issue 8
Submit an article Journal homepage
663
Views
43
CrossRef citations to date
0
Altmetric
Drug Evaluation

CPG-7909 (PF-3512676, ProMune®): toll-like receptor-9 agonist in cancer therapy

Yanal M Murad Duke University Medical Center, Department of Surgery, Program in Molecular Therapeutics, Comprehensive Cancer Center, 401 MSRB, Research Drive, Durham, NC 27710, USA [email protected]
, PhD,
Timothy M Clay Duke University Medical Center, Department of Surgery, Program in Molecular Therapeutics, Comprehensive Cancer Center, 401 MSRB, Research Drive, Durham, NC 27710, USA [email protected]
, PhD,
H Kim Lyerly Duke University Medical Center, Duke Comprehensive Cancer Center, Departments of Surgery, Pathology and Immunology, Program in Molecular Therapeutics, 401 MSRB, Research Drive, Durham, NC 27710, USA
, MD &
Michael A Morse Duke University Medical Center, Department of Medicine, Program in Molecular Therapeutics, Comprehensive Cancer Center, Box 3233, 401 MSRB, Research Drive, Durham, NC 27710, USA
, MD
Pages 1257-1266 | Published online: 14 Aug 2007

Bibliography

  • ABBAS AK, MURPHY KM, SHER A: Functional diversity of helper T lymphocytes. Nature (1996) 383(6603):787-793.
  • AKIRA S, TAKEDA K: Toll-like receptor signalling. Nat. Rev. Immunol. (2004) 4(7):499-511.
  • AKIRA S: TLR signaling. Innate Immun. Immunlologic. Mem. (2006) 311:1-16.
  • IWASAKI A, MEDZHITOV R: Toll-like receptor control of the adaptive immune responses. Nat. Immunol. (2004) 5(10):987-995.
  • TAKEDA K, KAISHO T, AKIRA S: Toll-like receptors. Annu. Rev. Immunol. (2003) 21:335-376.
  • MEDZHITOV R, PRESTON-HURLBURT P, JANEWAY CA Jr: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature (1997) 388(6640):394-397.
  • AKIRA S, TAKEDA K, KAISHO T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. (2001) 2(8):675-680.
  • WIEMANN B, STARNES CO: Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther. (1994) 64(3):529-564.
  • KRIEG AM: CpG motifs in bacterial DNA and their immune effects. Ann. Rev. Immunol. (2002) 20:709-760.
  • TOKUNAGA T, YAMAMOTO H, SHIMADA S et al.: Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Nat. Cancer Inst. (1984) 72(4):955-962.
  • YAMAMOTO S, KURAMOTO E, SHIMADA S, TOKUNAGA T: In vitro augmentation of natural killer cell activity and production of interferon-α/β and -γ with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn. J. Cancer Res. (1988) 79(7):866-873.
  • BAUER S, KIRSCHNING CJ, HACKER H et al.: Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. USA (2001) 98(16):9237-9242.
  • LEIFER CA, KENNEDY MN, MAZZONI A et al.: TLR9 is localized in the endoplasmic reticulum prior to stimulation. J. Immunol. (2004) 173(2):1179-1183.
  • LATZ E, SCHOENEMEYER A, VISINTIN A et al.: TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. (2004) 5(2):190-198.
  • AHMAD-NEJAD P, HACKER H, RUTZ M et al.: Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. (2002) 32(7):1958-1968.
  • ASSELIN-PATUREL C, BOONSTRA A, DALOD M et al.: Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat. Immunol. (2001) 2(12):1144-1150.
  • FAITH A, PEEK E, MCDONALD J et al.: Plasmacytoid dendritic cells from human lung cancer draining lymph nodes induce Tc1 responses. Am. J. Respir. Cell Mol. Biol. (2006) 36(3):360-367.
  • BERNASCONI NL, TRAGGIAI E, LANZAVECCHIA A: Maintenance of serological memory by polyclonal activation of human memory B cells. Science (2002) 298(5601):2199-2202.
  • BERNASCONI NL, ONAI N, LANZAVECCHIA A: A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood (2003) 101(11):4500-4504.
  • JUNG J, YI AK, ZHANG X et al.: Distinct response of human B cell subpopulations in recognition of an innate immune signal, CpG DNA. J. Immunol. (2002) 169(5):2368-2373.
  • YAO GQ, CORRIAS S, CHENG YC: Identification of two oligodeoxyribonucleotide binding proteins on plasma membranes of human cell lines. Biochem. Pharmacol. (1996) 51(4):431-436.
  • LAKTIONOV PP, DAZARD JE, VIVES E et al.: Characterisation of membrane oligonucleotide-binding proteins and oligonucleotide uptake in keratinocytes. Nucleic Acids Res. (1999) 27(11):2315-2324.
  • ZHU FG, REICH CF, PISETSKY DS: The role of the macrophage scavenger receptor in immune stimulation by bacterial DNA and synthetic oligonucleotides. Immunology (2001) 103(2):226-234.
  • LAMPHIER MS, SIROIS CM, VERMA A, GOLENBOCK DT, LATZ E: TLR9 and the recognition of self and non-self nucleic acids. Ann. NY Acad. Sci. (2006) 1082:31-43.
  • KRIEG AM, YI AK, MATSON S et al.: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 374(6522):546-549.
  • KRIEG AM: Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev.Drug Discov. (2006) 5(6):471-484.
  • YASUDA K, RUTZ M, SCHLATTER B et al.: CpG motif-independent activation of TLR9 upon endosomal translocation of “natural” phosphodiester DNA. Eur. J. Immunol. (2006) 36(2):431-436.
  • BARTON GM, KAGAN JC, MEDZHITOV R: Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat. Immunol. (2006) 7(1):49-56.
  • GUIDUCCI C, OTT G, CHAN JH et al.: Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J. Exp. Med. (2006) 203(8):1999-2008.
  • HACKER H, VABULAS RM, TAKEUCHI O et al.: Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J. Exp. Med. (2000) 192(4):595-600.
  • HACKER H, MISCHAK H, MIETHKE T et al.: CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. (1998) 17(21):6230-6240.
  • HACKER H: Signal transduction pathways activated by CpG-DNA. Curr. Top. Microbiol. Immunol. (2000) 247:77-92.
  • KATO A, HOMMA T, BATCHELOR J et al.: Interferon-α/β receptor-mediated selective induction of a gene cluster by CpG oligodeoxynucleotide 2006. BMC Immunol. (2003) 4:8.
  • KRUG A, ROTHENFUSSER S, SELINGER S et al.: CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells. J. Immunol. (2003) 170(7):3468-3477.
  • KERKMANN M, COSTA LT, RICHTER C et al.: Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-α induction by CpG-A in plasmacytoid dendritic cells. J. Biol. Chem. (2005) 280(9):8086-8093.
  • MARSHALL JD, FEARON K, ABBATE C et al.: Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J. Leukoc. Biol. (2003) 73(6):781-792.
  • HARTMANN G, BATTIANY J, POECK H et al.: Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-α induction in plasmacytoid dendritic cells. Eur. J. Immunol. (2003) 33(6):1633-1641.
  • YI AK, CHANG M, PECKHAM DW, KRIEG AM, ASHMAN RF: CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J. Immunol. (1998) 160(12):5898-5906.
  • RANKIN R, PONTAROLLO R, IOANNOU X et al.: CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nuclic Acid Drug Dev. (2001) 11(5):333-340.
  • HARTMANN G, KRIEG AM: Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. (2000) 164(2):944-953.
  • UHLMANN E, VOLLMER J: Recent advances in the development of immunostimulatory oligonucleotides. Curr. Opin. Drug Dis. Develop. (2003) 6(2):204-217.
  • MONTEITH DK, LEVIN AA: Synthetic oligonucleotides: the development of antisense therapeutics. Toxicol. Pathol. (1999) 27(1):8-13.
  • LEVIN AA: A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochimica et Biophysica Acta (1999) 1489(1):69-84.
  • BECKER Y: CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations – a review, hypothesis and implications. Virus Genes (2005) 30(2):251-266.
  • GEARY RS, LEEDS JM, HENRY SP, MONTEITH DK, LEVIN AA: Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des. (1997) 12(5):383-393.
  • COSSUM PA, SASMOR H, DELLINGER D et al.: Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. (1993) 267(3):1181-1190.
  • KRIEG AM, EFLER SM, WITTPOTH M, AL ADHAMI MJ, DAVIS HL: Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J. Immunother. (2004) 27(6):460-471.
  • HEMMI H, TAKEUCHI O, KAWAI T et al.: A Toll-like receptor recognizes bacterial DNA. Nature (2000) 408(6813):740-745.
  • KRIEG AM: Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr. Oncol. Rep. (2004) 6(2):88-95.
  • MILAS L, MASON KA, ARIGA H et al.: CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res. (2004) 64(15):5074-5077.
  • WANG XS, SHENG Z, RUAN YB, GUANG Y, YANG ML: CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma. World J. Gastroenterol. (2005) 11(8):1220-1224.
  • BALSARI A, TORTORETO M, BESUSSO D et al.: Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur. J. Cancer (2004) 40(8):1275-1281.
  • WEIGEL BJ, RODEBERG DA, KRIEG AM, BLAZAR BR: CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin. Cancer Res. (2003) 9(8):3105-3114.
  • WEERATNA RD, BOURNE LL, SULLIVAN SM, DAVIS HL, KRIEG AM: Combination of a new TLR9 agonist immunomodulator (CpG 7909) and paclitaxel for treatment of metastatic Lewis Lung Carcinoma (LLC). ASCO Meeting Abstracts (2004) 22(14 Suppl.):7346.
  • KIM SK, RAGUPATHI G, MUSSELLI C et al.: Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine (1999) 18(7-8):597-603.
  • CHU RS, TARGONI OS, KRIEG AM, LEHMANN PV, HARDING CV: CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. (1997) 186(10):1623-1631.
  • HE B, QIAO X, CERUTTI A: CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J. Immunol. (2004) 173(7):4479-4491.
  • WEERATNA R, COMANITA L, DAVIS HL: CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice. Immunol. Cell Biol. (2003) 81(1):59-62.
  • DAVIS HL, WEERATNA R, WALDSCHMIDT TJ et al.: CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. (1998) 160(2):870-876.
  • KLINE JN, WALDSCHMIDT TJ, BUSINGA TR et al.: Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. (1998) 160(6):2555-2559.
  • JAIN VV, KITAGAKI K, BUSINGA T et al.: CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma. J. Allergy Clin. Immunol. (2002) 110(6):867-872.
  • THOMPSON JA, KUZEL T, BUKOWSKI R, MASCIARI F, SCHMALBACH T: Phase Ib trial of a targeted TLR9 CpG immunomodulator (CPG 7909) in advanced renal cell carcinoma (RCC). ASCO Meeting Abstracts (2004) 22(14 Suppl.):4644.
  • VAN DEN EERTWEGH AJ, LENSEN RJ, SCHEPER RJ et al.: Autologous tumor cell vaccination with PF-3512676 (CPG 7909) and GM-CSF followed by subcutaneous PF-3512676 and IFN-α for patients with metastatic renal cell carcinoma. ASCO Meeting Abstracts (2006) 24(18 Suppl.):2530.
  • WOOLDRIDGE JE, BALLAS Z, KRIEG AM, WEINER GJ: Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood (1997) 89(8):2994-2998.
  • WARREN TL, DAHLE CE, WEINER GJ: CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. Clin. Lymphoma (2000) 1(1):57-61.
  • WEINER GJ, LINK BK, LEONARD J et al.: Combination of CpG7909 and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL): a Phase I, open label dose-escalation study of safety and tolerability. ASCO Meeting Abstracts (2004) 22(14 Suppl.):6594-.
  • LINK BK, BALLAS ZK, WEISDORF D et al.: Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother. (2006) 29(5):558-568.
  • WOOLDRIDGE BKL J, WEISDORF DJ, BALLAS ZK et al.: Phase I study of oligodeoxynucleotide CpG 7909 in patients with previously treated non-Hodgkin's lymphoma. Proc. Am. Soc. Clin. Oncol. (2003) 22:2003.
  • SPEISER DE, LIENARD D, RUFER N et al.: Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. (2005) 115(3):739-746.
  • WAGNER S, WEBER J, REDMAN B et al.: CPG 7909, a TLR9 agonist immunomodulator in metastatic melanoma: a randomized Phase II trial comparing two doses and in combination with DTIC. ASCO Meeting Abstracts (2005) 23(16 Suppl.):7526.
  • PASHENKOV M, GOESS G, WAGNER C et al.: Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol. (2006) 24(36):5716-5724.
  • WAGNER SN, PASHENKOV M, GOESS G et al.: TLR9-targeted CpG immunostimulatory treatment of metastatic melanoma: a Phase II trial with CpG 7909 (ProMune). ASCO Meeting Abstracts (2004) 22(14 Suppl):7513.
  • THERASSE P, ARBUCK SG, EISENHAUER EA et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. (2000) 92(3):205-216.
  • HAYASHI T, RAZ E: TLR9-based immunotherapy for allergic disease. Am. J. Med. (2006) 119(10)
  • CRETICOS PS, CHEN YH, SCHROEDER JT: New approaches in immunotherapy: allergen vaccination with immunostimulatory DNA. Immunol. Allergy Clin. North Am. (2004) 24(4):569-581.
  • SIMONS FE, SHIKISHIMA Y, VAN NEST G, EIDEN JJ, HAYGLASS KT: Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol. (2004) 113(6):1144-1151.
  • MCHUTCHINSON J, BACON B, GORDON S et al.: Relationships of HCV responses to CPG 10101, a TLR9 agonist: pharmacodynamics and patient characteristics. Hepatology (Baltimore, MD) (2005) 42(4 Suppl. 1):A249.
  • HALPERIN SA, VAN NEST G, SMITH B et al.: A Phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine (2003) 21(19-20):2461-2467.
  • COOPER CL, DAVIS HL, MORRIS ML et al.: CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind Phase I/II study. J. Clin. Immunol. (2004) 24(6):693-701.
  • FRIEDBERG JW, KIM H, MCCAULEY M et al.: Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-α/β-inducible gene expression, without significant toxicity. Blood (2005) 105(2):489-495.
  • HWANG JJ, PARK S, AMIN A et al.: A Phase I study of HYB2055 in patients (pts) with advanced solid malignancies. ASCO Meeting Abstracts (2004) 22(14 Suppl.):3111.
  • KRIEG AM: Development of TLR9 agonists for cancer therapy. J. Clin. Invest. (2007) 117(5):1184-1194.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.